Emerging Drug Developer: Ambit Biosciences
Ambit Biosciences has taken another important step forward. In the middle of last month, CEO Scott Salka announced that it had garnered about $50 million in its fourth round. That money should be enough to get the company through 2009, a key transition period for Ambit. "We're expecting at least clinical proof of concept and completion of that milestone with one compound by the end of '09." Salka tells FierceBiotech, which named Ambit a Fierce 15 company in 2006. Article